RNA metabolism in ALS: When normal processes become pathological

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 15, Issue 5-6, 2014, Pages 321-336

  Droppelmann, Cristian A ^a   Campos Melo, Danae ^a   Ishtiaq, Muhammad ^a   Volkening, Kathryn ^a,b   Strong, Michael J ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

ALS; Neuronal cytoplasmic inclusions; Post translational modifications; RNA metabolism; Stress granule

Indexed keywords

ADENOSINE DEAMINASE; MICRORNA; RNA; RNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; BIOGENESIS; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DOWN REGULATION; FRONTOTEMPORAL DEMENTIA; INFORMATION RETRIEVAL; METHYLATION; MOTONEURON; NERVE CELL NECROSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW; RNA EDITING; RNA METABOLISM; RNA PROCESSING; SPLICEOSOME; SUMOYLATION; GENETICS; HUMAN; METABOLISM;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; RNA;

EID: 84906354951     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2014.881377     Document Type: Review

References (215)

1. Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: A proteinopathy? J Neuropathol Exp Neurol. 2005; 64: 649-64
2. Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, et al. Rate of familial amyotrophic lateral sclerosis: A systematic review and meta-Analysis. JNeurol Neurosurg Psychiatry. 2011; 82: 623-7
3. Rosen D R, Siddique T, Patterson D, Figlewicz D A, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362: 59-62
4. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008; 40: 572-4
5. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008; 319: 1668-72
6. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009; 323: 1205-8
7. Vance C, Rogelj B, Hortobagyi T, de Vos K J, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009; 323: 1208-11
8. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011; 477: 211-5
9. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010; 465: 223-6
10. Sleegers K, Brouwers N, Maurer-Stroh S, van Es MA, Van Damme P, Van Vught PW, et al. Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology. 2008; 71: 253-9
11. Wu C H, Fallini C, Ticozzi N, Keagle P J, Sapp P C, Piotrowska K, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012; 488: 499-503
12. Zhao ZH, Chen WZ, Wu ZY, Wang N, Zhao G X, Chen WJ, et al. Anovel mutation in the senataxin gene identified in a Chinese patient with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009; 10: 118-22
13. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010; 68: 857-64
14. Droppelmann CA, Wang J, Campos-Melo D, Keller B, Volkening K, Hegele RA, et al. Detection of a novel frameshift mutation and regions with homozygosis within ARHGEF28 gene in familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14: 444-51
15. Kim HJ, Kim NC, Wang Y D, Scarborough EA, Moore J, Diaz Z, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013; 495: 467-73
16. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in non-coding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011; 72: 245-56
17. Renton A E, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. Ahexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72: 257-68
18. Blokhuis AM, Groen E J, Koppers M, Van Den Berg L H, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013; 125: 777-94
19. Strong MJ. The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). JNeurol Sci. 2010; 288: 1-12
20. Polymenidou M, Lagier-Tourenne C, Hutt K R, Bennett CF, Cleveland DW, Yeo GW. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res. 2012; 1462: 3-15
21. Van Blitterswijk M, Landers J E. RNA processing pathways in amyotrophic lateral sclerosis. Neurogenetics. 2010; 11: 275-90
22. Couthouis J, Hart MP, Shorter J, DeJesus-Hernandez M, Erion R, Oristano R, et al. Ayeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A. 2011; 108: 20881-90
23. Collins M, Riascos D, Kovalik T, An J, Krupa K, Hood BL, et al. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients. Acta Neuropathol. 2012; 124: 717-32
24. Droppelmann CA, Keller BA, Campos-Melo D, Volkening K, Strong MJ. Rho guanine nucleotide exchange factor is an NFLmRNA destabilizing factor that forms cytoplasmic inclusions in amyotrophic lateral sclerosis. Neurobiol Aging. 2013; 34: 248-62
25. Keller BA, Volkening K, Droppelmann CA, Ang LC, Rademakers R, Strong MJ. Co-Aggregation of RNA binding proteins in ALS spinal motor neurons: Evidence of a common pathogenic mechanism. Acta Neuropathol. 2012; 124: 733-47
26. Donnelly CJ, Zhang PW, Pham JT, Heusler AR, Mistry NA, Vidensky S, et al. RNA toxicity from the ALS/ FTD C9orf72 expansion is mitigated by antisense intervention. Neuron. 2013; 80: 415-28
27. Lee Y B, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M, et al. Hexanucleotide Repeats in ALS/FTD Form Length-Dependent RNA Foci, Sequester RNA Binding Proteins, and Are Neurotoxic. Cell Rep. 2013; 12: 1178-86
28. Dreyfuss G, Kim V N, Kataoka N. Messenger-RNAbinding proteins and the messages they carry. Nat Rev Mol Cell Biol. 2002; 3: 195-205
29. Buratti E, Baralle FE. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci. 2008; 13: 867-78
30. Colombrita C, Onesto E, Megiorni F, Pizzuti A, Baralle FE, Buratti E, et al. TDP-43 and FUS RNAbinding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-Transcriptional fate in motoneuron-like cells. JBiol Chem. 2012; 287: 15635-47
31. Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A. 2012; 109: 3347-52
32. Morlando M, Dini Modigliani S, Torrelli G, Rosa A, Di Carlo V, Caffarelli E, et al. FUS stimulates microRNA biogenesis by facilitating cotranscriptional Drosha recruitment. EMBO J. 2012; 31: 4502-10
33. Law W J, Cann K L, Hicks G G. TLS, EWS and TAF15: A model for transcriptional integration of gene expression. Brief Funct Genomic Proteomic. 2006; 5: 8-14
34. Leichter M, Marko M, Ganou V, Patrinou-Georgoula M, Tora L, Guialis A. Afraction of the transcription factor TAF15 participates in interactions with a subset of the spliceosomal U1 snRNP complex. Biochim Biophys Acta. 2011; 1814: 1812-24
35. Ballarino M, Jobert L, Dembele D, de la G range P, Auboeuf D, Tora L. TAF15 is important for cellular proliferation and regulates the expression of a subset of cell cycle genes through miRNAs. Oncogene. 2013; 32: 4646-55
36. Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. JNeurochem. 2009; 111: 1051-61
37. Blechingberg J, Luo Y, Bolund L, Damgaard CK, Nielsen AL. Gene expression responses to FUS, EWS, and TAF15 reduction and stress granule sequestration analyses identifies FET-protein non-redundant functions. PLoS One. 2012; 7: E46251
38. Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito H, Takekawa M. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nat Cell Biol. 2008; 10: 1324-32
39. Wehner KA, Schutz S, Sarnow P. OGFOD1, anovel modulator of eukaryotic translation initiation factor 2alpha phosphorylation and the cellular response to stress. Mol Cell Biol. 2010; 30: 2006-16
40. Pizzo E, Sarcinelli C, Sheng J, Fusco S, Formiggini F, Netti P, et al. Ribonuclease/angiogenin inhibitor 1 regulates stress-induced subcellular localization of angiogenin to control growth and survival. JCell Sci. 2013; 126: 4308-19
41. Solomon S, Xu Y, Wang B, David MD, Schubert P, Kennedy D, et al. Distinct structural features of caprin-1 mediate its interaction with G3BP-1 and its induction of phosphorylation of eukaryotic translation initiation factor 2-Alpha, entry to cytoplasmic stress granules, and selective interaction with a subset of mRNAs. Mol Cell Biol. 2007; 27: 2324-42
42. Parker R, Sheth U. P-bodies and the control of mRNA translation and degradation. Mol Cell. 2007; 25: 635-46
43. Kedersha N, Stoecklin G, Ayodele M, Yacono P, Lykke-Andersen J, Fritzler MJ, et al. Stress granules and processing bodies are dynamically linked sites of mRNP remodelling. JCell Biol. 2005; 169: 871-84
44. Anderson P, Kedersha N. Stress granules: The Tao of RNA triage. Trends Biochem Sci. 2008; 33: 141-50
45. Kedersha N, Chen S, Gilks N, Li W, Miller I J, Stahl J, et a l. Evidence that ternary complex (eIF2-GTP-TRNA(i) (Met))-deficient preinitiation complexes are core constituents of mammalian stress granules. Mol Biol Cell. 2002; 13: 195-210
46. Kedersha NL, Gupta M, Li W, Miller I, Anderson P. RNAbinding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 alpha to the assembly of mammalian stress granules. JCell Biol. 1999; 147: 1431-42
47. Wilczynska A, Aigueperse C, Kress M, Dautry F, Weil D. The translational regulator CPEB1 provides a link between dcp1 bodies and stress granules. JCell Sci. 2005; 118: 981-92
48. Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D, Yaspo ML, et al. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell. 2007; 18: 1385-96
49. Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WF, Blackwell TK, et al. MK2-induced tristetraprolin: 14-3-3 complexes prevent stress granule association and AREmRNA decay. EMBO J. 2004; 23: 1313-24
50. Stohr N, Lederer M, Reinke C, Meyer S, Hatzfeld M, Singer RH, et al. ZBP1 regulates mRNA stability during cellular stress. JCell Biol. 2006; 175: 527-34
51. Leung AK, Calabrese J M, Sharp P A. Quantitative analysis of Argonaute protein reveals microRNA-dependent localization to stress granules. Proc Natl Acad Sci U S A. 2006; 103: 18125-30
52. Tourriere H, Chebli K, Zekri L, Courselaud B, Blanchard JM, Bertrand E, et al. The RasGAP-Associated endoribonuclease G3BP assembles stress granules. JCell Biol. 2003; 160: 823-31
53. Baguet A, Degot S, Cougot N, Bertrand E, Chenard MP, Wendling C, et al. The exon-junction-complex-component metastatic lymph node 51 functions in stress-granule assembly. JCell Sci. 2007; 120: 2774-84
54. Yu C, York B, Wang S, Feng Q, Xu J, O'Malley BW. An essential function of the SRC-3 coactivator in suppression of cytokine mRNA translation and inflammatory response. Mol Cell. 2007; 25: 765-78
55. Yang F, Peng Y, Murray E L, Otsuka Y, Kedersha N, Schoenberg DR. Polysome-bound endonuclease PMR1 is targeted to stress granules via stress-specific binding to TIA-1. Mol Cell Biol. 2006; 26: 8803-13
56. Souquere S, Mollet S, Kress M, Dautry F, Pierron G, Weil D. Unravelling the ultrastructure of stress granules and associated P-bodies in human cells. JCell Sci. 2009; 122: 3619-26
57. Raaben M, Groot Koerkamp MJ, Rottier PJ, de Haan CA. Mouse hepatitis coronavirus replication induces host translational shut-off and mRNA decay, with concomitant formation of stress granules and processing bodies. Cell Microbiol. 2007; 9: 2218-29
58. Loschi M, Leishman CC, Berardone N, Boccaccio GL. Dynein and kinesin regulate stress-granule and P-body dynamics. JCell Sci. 2009; 122: 3973-82
59. Kedersha N, Cho M R, Li W, Yacono P W, Chen S, Gilks N, et al. Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA to mammalian stress granules. JCell Biol. 2000; 151: 1257-68
60. Cougot N, Babajko S, Seraphin B. Cytoplasmic foci are sites of mRNA decay in human cells. JCell Biol. 2004; 165: 31-40
61. Andrei MA, Ingelfinger D, Heintzmann R, Achsel T, Rivera-Pomar R, Luhrmann R. Arole for eIF4E and eIF4E-Transporter in targeting mRNPs to mammalian processing bodies. RNA. 2005; 11: 717-27
62. Bashkirov VI, Scherthan H, Solinger JA, Buerstedde JM, Heyer WD. Amouse cytoplasmic exoribonuclease (mXRN1p) with preference for G4 tetraplex substrates. JCell Biol. 1997; 136: 761-73
63. Van Dijk E, Cougot N, Meyer S, Babajko S, Wahle E, Seraphin B. Human Dcp2: A catalytically active mRNA decapping enzyme located in specific cytoplasmic structures. EMBO J. 2002; 21: 6915-24
64. Zheng D, Ezzeddine N, Chen CY, Zhu W, He X, Shyu A B. Deadenylation is prerequisite for P-body formation and mRNA decay in mammalian cells. JCell Biol. 2008; 182: 89-101
65. Stoecklin G, Kedersha N. Relationship of GW/P-bodies with stress granules. Adv Exp Med Biol. 2013; 768: 197-211
66. Kulkarni M, Ozgur S, Stoecklin G. On track with P-bodies. Biochem Soc Trans. 2010; 38: 242-51
67. Buchan JR, Muhlrad D, Parker R. P-bodies promote stress granule assembly in Saccharomyces cerevisiae. JCell Biol. 2008; 183: 441-55
68. Serman A, Le Roy F, Aigueperse C, Kress M, Dautry F, Weil D. GW body disassembly triggered by siRNAs independently of their silencing activity. Nucleic Acids Res. 2007; 35: 4715-27
69. Ayala Y M, Zago P, D'Ambrogio A, Xu Y F, Petrucelli L, Buratti E, et al. Structural determinants of the cellular localization and shuttling of TDP-43. JCell Sci. 2008; 121: 3778-85
70. Zinszner H, Sok J, Immanuel D, Yin Y, Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. JCell Sci. 1997; 110: 1741-50
71. Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, Mehta T, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: Analysis of cultured cells and pathological brain tissue. PLoS One. 2010; 5: E13250
72. Freibaum BD, Chitta RK, High A A, Taylor JP. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. JProteome Res. 2010; 9: 1104-20
73. Dewey CM, Cenik B, Sephton CF, Dries DR, Mayer P 3rd, Good SK, et al. TDP-43 is directed to stress granules by sorbitol, anovel physiological osmotic and oxidative stressor. Mol Cell Biol. 2011; 31: 1098-108
74. Meyerowitz J, Parker S J, Vella L J, Ng D, Price KA, Liddell JR, et al. C-Jun N-Terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress. Mol Neurodegener. 2011; 6: 57
75. McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, et al. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet. 2011; 20: 1400-10
76. Aulas A, Stabile S, VandeVelde C. Endogenous TDP-43, but not FUS, contributes to stress granule assembly via G3BP. Mol Neurodegener. 2012; 7: 54
77. Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNAbinding protein of 43 kDa (TDP-43). JBiol Chem. 2012; 287: 23079-94
78. Nishimoto Y, Ito D, Yagi T, Nihei Y, Tsunoda Y, Suzuki N. Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. JBiol Chem. 2010; 285: 608-19
79. Yamaguchi A, Kitajo K. The effect of PRMT1-mediated arginine methylation on the subcellular localization, stress granules, and detergent-insoluble aggregates of FUS/TLS. PLoS One. 2012; 7: E49267
80. Sama RR, Ward CL, Kaushansky LJ, Lemay N, Ishigaki S, Urano F, et al. FUS/TLS assembles into stress granules and is a prosurvival factor during hyperosmolar stress. JCell Physiol. 2013; 228: 2222-31
81. Gal J, Zhang J, Kwinter D M, Zhai J, Jia H, Jia J, et a l. Nuclear localization sequence of FUS and induction of stress granules by ALS mutants. Neurobiol Aging. 2011; 32: 2323, e27-40
82. Bosco D A, Lemay N, Ko H K, Zhou H, Burke C, Kwiatkowski TJ Jr, et al. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol Genet. 2010; 19: 4160-75
83. Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, et al. ALS-Associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010; 29: 2841-57
84. Baron DM, Kaushansky L J, Ward C L, Sama R R, Chian RJ, Boggio KJ, et al. Amyotrophic lateral sclerosis-linked FUS/ TLS alters stress granule assembly and dynamics. Mol Neurodegener. 2013; 8: 30
85. Andersson MK, Stahlberg A, Arvidsson Y, Olofsson A, Semb H, Stenman G, et al. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol. 2008; 9: 37
86. Marko M, Vlassis A, Guialis A, Leichter M. Domains involved in TAF15 subcellular localization: Dependence on cell type and ongoing transcription. Gene. 2012; 506: 331-8
87. Ralser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, Krobitsch S. An integrative approach to gain insights into the cellular function of human Ataxin-2. J Mol Biol. 2005; 346: 203-14
88. Albrecht M, Golatta M, Wullner U, Lengauer T. Structural and functional analysis of Ataxin-2 and Ataxin-3. Eur J Biochem. 2004; 271: 3155-70
89. Elden A C, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010; 466: 1069-75
90. Ripmaster TL, Vaughn G P, Woolford J L J r. Aputative ATP-dependent RNA helicase involved in Saccharomyces cerevisiae ribosome assembly. Proc Natl Acad Sci USA. 1992; 89: 11131-5
91. Mazroui R, Sukarieh R, Bordeleau ME, Kaufman RJ, Northcote P, Tanaka J, et al. Inhibition of ribosome recruitment induces stress granule formation independently of eukaryotic initiation factor 2-Alpha phosphorylation. Mol Biol Cell. 2006; 17: 4212-9
92. Parker SJ, Meyerowitz J, James JL, Liddell JR, Crouch PJ, Kanninen KM, et al. Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem Int. 2012; 60: 415-24
93. Volkening K, Leystra-Lantz C, Yang W, Jaffee H, Strong MJ. TAR DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFLmRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res. 2009; 1305: 168-82
94. DePace AH, Santoso A, Hillner P, Weissman JS. Acritical role for amino-Terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion. Cell. 1998; 93: 1241-52
95. Polymenidou M, Cleveland DW. The seeds of neurodegeneration: Prion-like spreading in ALS. Cell. 2011; 147: 498-508
96. King O D, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012; 1462: 61-80
97. Udan-Johns M, Bengoechea R, Bell S, Shao J, Diamond MI, True HL, et al. Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. Hum Mol Genet. 2013; 23: 157-70
98. Johnson B S, Snead D, Lee J J, McCaffery J M, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. JBiol Chem. 2009; 284: 20329-39
99. Guo W, Chen Y, Zhou X, Kar A, Ray P, Chen X, et al. An ALS-Associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol. 2011; 18: 822-30
100. Vance C, Scotter EL, Nishimura AL, Troakes C, Mitchell JC, Kathe C, et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-Type FUS within cytoplasmic stress granules. Hum Mol Genet. 2013; 22: 2676-88
101. Trojsi F, Monsurro MR, Tedeschi G. Exposure to environmental toxicants and pathogenesis of amyotrophic lateral sclerosis: State of the art and research perspectives. Int J Mol Sci. 2013; 14: 15286-311
102. Alfahad T, Nath A. Retroviruses and amyotrophic lateral sclerosis. Antiviral Res. 2013; 99: 180-7
103. Williams LR. Oxidative stress, age-related neurodegeneration, and the potential for neurotrophic treatment. Cerebrovasc Brain Metab Rev. 1995; 7: 55-73
104. Nunomura A, Moreira P I, Castellani R J, Lee H G, Zhu X, Smith MA, et al. Oxidative damage to RNA in aging and neurodegenerative disorders. Neurotox Res. 2012; 22: 231-48
105. Weingarten M D, Lockwood AH, Hwo S Y, Kirschner M W. Aprotein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975; 72: 1858-62
106. Ihara Y, Nukina N, Miura R, Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. JBiochem. 1986; 99: 1807-10
107. Murayama S, Mori H, Ihara Y, Tomonaga M. Immunocytochemical and ultrastructural studies of Pick's disease. Ann Neurol. 1990; 27: 394-405
108. Harrington C R, Perry R H, Perry E K, Hurt J, McKeith I G, Roth M, et al. Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia. 1994; 5: 215-28
109. Ikeda K, Akiyama H, Haga C, Kondo H, Arima K, Oda T. Argyrophilic thread-like structure in corticobasal degeneration and supranuclear palsy. Neurosci Lett. 1994; 174: 157-9
110. Strong MJ, Yang W, Strong WL, Leystra-Lantz C, Jaffe H, Pant HC. Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment. Neurology. 2006; 66: 1770-1
111. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-Assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A. 2001; 98: 6923-8
112. Mendieta J, Fuertes MA, Kunjishapatham R, Santa-Maria I, Moreno FJ, Alonso C, et al. Phosphorylation modulates the alpha-helical structure and polymerization of a peptide from the third tau microtubule-binding repeat. Biochim Biophys Acta. 2005; 1721: 16-26
113. Sun Q, Gamblin TC. Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization. Biochemistry. 2009; 48: 6002-11
114. Combs B, Voss K, Gamblin T C. Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms. Biochemistry. 2011; 50: 9446-56
115. Inukai Y, Nonaka T, Arai T, Yoshida M, Hashizume Y, Beach TG, et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett. 2008; 582: 2899-904
116. Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008; 64: 60-70
117. Neumann M, Kwong L K, Lee E B, Kremmer E, Flatley A, Xu Y, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009; 117: 137-49
118. Liachko N F, Guthrie C R, Kraemer B C. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. JNeurosci. 2010; 30: 16208-19
119. Zhang YJ, Gendron TF, Xu YF, Ko L W, Yen S H, Petrucelli L. Phosphorylation regulates proteasomalmediated degradation and solubility of TAR DNA binding protein-43 C-Terminal fragments. Mol Neurodegener. 2010; 5: 33
120. Brady OA, Meng P, Zheng Y, Mao Y, Hu F. Regulation of TDP-43 aggregation by phosphorylation and p62/ SQSTM1. JNeurochem. 2011; 116: 248-59
121. Braak H, Ludolph A, Thal DR, del Tredici K. Amyotrophic lateral sclerosis: Dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. Acta Neuropathol. 2010; 120: 67-74
122. Li H Y, Yeh P A, Chiu H C, Tang C Y, Tu B P. Hyperphosphorylation as a defence mechanism to reduce TDP-43 aggregation. PLoS One. 2011; 6: E23075
123. Choksi DK, Roy B, Chatterjee S, Yusuff T, Bakhoum MF, Sengupta U, et al. TDP-43 Phosphorylation by casein kinase I{epsilon} promotes oligomerization and enhances toxicity in vivo. Hum Mol Genet. 2014; 23: 1025-35
124. Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. JMol Biol. 1999; 294: 135-62
125. Toombs J A, Petri M, Paul K R, Kan G Y, Ben-Hur A, Ross ED. De novo design of synthetic prion domains. Proc Natl Acad Sci U S A. 2012; 109: 6519-24
126. Prilusky J, Felder CE, Zeev-Ben-Mordehai T, Rydberg EH, Man O, Beckmann JS, et al. FoldIndex: A simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics. 2005; 21: 3435-8
127. Hay RT. SUMO: A history of modification. Mol Cell. 2005; 18: 1-12
128. Johnson ES. Protein modification by SUMO. Annu Rev Biochem. 2004; 73: 355-82
129. Martin S, Wilkinson KA, Nishimune A, Henley JM. Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction. Nat Rev Neurosci. 2007; 8: 948-59
130. Datwyler AL, Lattig-Tunnemann G, Yang W, Paschen W, Lee SL, Dirnagl U, et al. SUMO2/3 conjugation is an endogenous neuroprotective mechanism. JCereb Blood Flow Metab. 2011; 31: 2152-9
131. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, et al. Amyotrophic lateral sclerosis and structural defects in Cu/Zn superoxide dismutase. Science. 1993; 261: 1047-51
132. Stieber A, Gonatas JO, Gonatas NK. Aggregates of mutant protein appear progressively in dendrites, in periaxonal processes of oligodendrocytes, and in neuronal and astrocytic perikarya of mice expressing the SOD1-G93A mutation of familial amyotrophic lateral sclerosis. JNeurol Sci. 2000; 177: 114-23
133. Shaw BF, Lelie HL, Durazo A, Nersissian A M, Xu G, Chan PK, et al. Detergent-insoluble aggregates associated with amyotrophic lateral sclerosis in transgenic mice contain primarily full-length, unmodified superoxide dismutase-1. JBiol Chem. 2008; 283: 8340-50
134. Fei E, Jia N, Yan M, Ying Z, Sun Q, Wang H, et al. SUMO-1 modification increases human SOD1 stability and aggregation. Biochem Biophys Res Commun. 2006; 347: 406-12
135. Seyfried N T, Gozal Y M, Dammer E B, Xia Q, Duong D M, Cheng D, et al. Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. Mol Cell Proteomics. 2010; 9: 705-18
136. Golebiowski F, Matic I, Tatham MH, Cole C, Yin Y, Nakamura A, et al. System-wide changes to SUMO modifications in response to heat shock. Sci Signal. 2009; 2: Ra24
137. Oh S M, Liu Z, Okada M, Jang S W, Liu X, Chan C B, et a l. Ebp1 sumoylation, regulated by TLS/FUS E3 ligase, is required for its anti-proliferative activity. Oncogene. 2010; 29: 1017-30
138. Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y, Dejean A. c-Jun and p53 activity is modulated by SUMO-1 modification. JBiol Chem. 2000; 275: 13321-9
139. Everett R D, Lomonte P, Sternsdorf T, Van Driel R, Orr A. Cell cycle regulation of PML modification and ND10 composition. JCell Sci. 1999; 112: 4581-8
140. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell. 1998; 2: 233-9
141. Xue Y, Zhou F, Fu C, Xu Y, Yao X. SUMOsp: A web server for sumoylation site prediction. Nucleic Acids Res. 2006; 34: W254-7
142. Gary J D, Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog Nucleic Acid Res Mol Biol. 1998; 61: 65-131
143. Wolf SS. The protein arginine methyltransferase family: An update about function, new perspectives and the physiological role in humans. Cell Mol Life Sci. 2009; 66: 2109-21
144. J, Frankel A, Cook R J, Kim S, Paik W K, Williams KR, et al. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. JBiol Chem. 2000; 275: 7723-30
145. Najbauer J, Johnson BA, Young A L, Aswad DW. Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins. JBiol Chem. 1993; 268: 10501-9
146. Liu Q, Dreyfuss G. In vivo and in vitro arginine methylation of RNA-binding proteins. Mol Cell Biol. 1995; 15: 2800-8
147. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, et al. Regulation of transcription by a protein methyltransferase. Science. 1999; 284: 2174-7
148. Tradewell ML, Yu Z, Tibshirani M, Boulanger MC, Durham HD, Richard S. Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum Mol Genet. 2012; 21: 136-49
149. Dormann D, Madl T, Valori C F, Bentmann E, Tahirovic S, Abou-Ajram C, et al. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 2012; 31: 4258-75
150. Jobert L, Argentini M, Tora L. PRMT1 mediated methylation of TAF15 is required for its positive gene regulatory function. Exp Cell Res. 2009; 315: 1273-86
151. Starega-Roslan J, Koscianska E, Kozlowski P, Krzyzosiak WJ. The role of the precursor structure in the biogenesis of microRNA. Cell Mol Life Sci. 2011; 68: 2859-71
152. Buratti E, de Conti L, Stuani C, Romano M, Baralle M, Baralle F. Nuclear factor TDP-43 can affect selected micro-RNA levels. FEBS J. 2010; 277: 2268-81
153. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10: 126-39
154. Laneve P, di Marcotullio L, Gioia U, Fiori ME, Ferretti E, Gulino A, et al. The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci U S A. 2007; 104: 7957-62
155. Packer A N, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA miR-9/miR-9 regulates REST and CoREST and is down-regulated in Huntington's disease. JNeurosci. 2008; 28: 14341-6
156. Pathania M, Torres-Reveron J, Yan L, Kimura T, Lin TV, Gordon V, et al. miR-132 enhances dendritic morphogenesis, spine density, synaptic integration, and survival of newborn olfactory bulb neurons. PLoS One. 2012; 7: E38174
157. Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, et al. Regulation of synaptic structure and function by FMRP-Associated microRNAs miR-125b and miR-132. Neuron. 2010; 65: 373-84
158. Li Z, Lu Y, Xu XL, Gao FB. The FTD/ALS-Associated RNA-binding protein TDP-43 regulates the robustness of neuronal specification through microRNA-9a in Drosophila. Hum Mol Genet. 2013; 22: 218-25
159. Cheloufi S, Dos Santos C O, Chong M M, Hannon G J. ADicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010; 465: 584-9
160. Cifuentes D, Xue H, Taylor D W, Patnode H, Mishima Y, CheloufiS, et al. Anovel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science. 2010; 328: 1694-8
161. Tao J, Wu H, Lin Q, Wei W, Lu X H, Cantle J P, et a l. Deletion of astroglial Dicer causes non-cell-Autonomous neuronal dysfunction and degeneration. JNeurosci. 2011; 31: 8306-19
162. Shin D, Shin J Y, McManus MT, Ptacek LJ, Fu YH. Dicer ablation in oligodendrocytes provokes neuronal impairment in mice. Ann Neurol. 2009; 66: 843-57
163. Wu D, Raafat A, Pak E, Clemens S, Murashov AK. Dicer-microRNA pathway is critical for peripheral nerve regeneration and functional recovery in vivo and regenerative axonogenesis in vitro. Exp Neurol. 2012; 233: 555-65
164. Campos-Melo D, Droppelmann C A, He Z, Volkening K, Strong MJ. Altered microRNA expression profile in amyotrophic lateral sclerosis: A role in the regulation of NFLmRNA levels. Mol Brain. 2013; 6: 26
165. de Felice B, Guida M, Coppola C, de Mieri G, Cotrufo R. AmiRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene. 2012; 508: 35-40
166. Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. JClin Invest. 2012; 122: 3063-87
167. Shioya M, Obayashi S, Tabunoki H, Arima K, Saito Y, Ishida T, et al. Aberrant microRNA expression in the brains of neurodegenerative diseases: MiR-29a decreased in Alzheimer's disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol. 2010; 36: 320-30
168. Freischmidt A, Muller K, Ludolph A C, Weishaupt JH. Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2013; 1: 42
169. Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular
170. Zhou F, Guan Y, Chen Y, Zhang C, Yu L, Gao H, et al. miRNA-9 expression is up-regulated in the spinal cord of G93A-SOD1 transgenic mice. Int J Clin Exp Pathol. 2013; 6: 1826-38
171. Koval ED, Shaner C, Zhang P, du Maine X, Fischer K, Tay J, et al. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet. 2013; 22: 4127-35
172. Polymenidou M, Lagier-Tourenne C, Hutt K R, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011; 14: 459-68
173. Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011; 14: 452-8
174. Ishihara T, Ariizumi Y, Shiga A, Kato T, Tan C F, Sato T, et al. Decreased number of Gemini of coiled bodies and U12 snRNA level in amyotrophic lateral sclerosis. Hum Mol Genet. 2013; 22: 4136-47
175. Tsuiji H, Iguchi Y, Furuya A, Kataoka A, Hatsuta H, Atsuta N, et al. Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol Med. 2013; 5: 221-34
176. Wang IF, Reddy NM, Shen CK. Higher order arrangement of the eukaryotic nuclear bodies. Proc Natl Acad Sci USA. 2002; 99: 13583-8
177. Cohen TJ, Hwang AW, Unger T, Trojanowski J Q, Lee V M. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J. 2012; 31: 1241-52
178. Gray M W. Evolutionary origin of RNA editing. Biochemistry. 2012; 51: 5235-42
179. Mallela A, Nishikura K. A-To-I editing of protein coding and non-coding RNAs. Crit Rev Biochem Mol Biol. 2012; 47: 493-501
180. Melcher T, Maas S, Herb A, Sprengel R, Higuchi M, Seeburg PH. RED2, abrain-specific member of the RNA-specific adenosine deaminase family. JBiol Chem. 1996; 271: 31795-8
181. Schumacher JM, Lee K, Edelhoff S, Braun RE. Distribution of Tenr, an RNA-binding protein, in a lattice-like network within the spermatid nucleus in the mouse. Biol Reprod. 1995; 52: 1274-83
182. Hogg M, Paro S, Keegan LP, O'Connell MA. RNA editing by mammalian ADARs. Adv Genet. 2011; 73: 87-120
183. Sommer B, Kohler M, Sprengel R, Seeburg P H. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell. 1991; 67: 11-9
184. Hideyama T, Yamashita T, Aizawa H, Tsuji S, Kakita A, Takahashi H, et al. Profound down-regulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis. 2012; 45: 1121-8
185. Akbarian S, Smith MA, Jones EG. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. Brain Res. 1995; 699: 297-304
186. Kwak S, Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. JMol Med (Berl). 2005; 83: 110-20
187. Aizawa H, Sawada J, Hideyama T, Yamashita T, Katayama T, Hasebe N, et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol. 2010; 120: 75-84
188. Hideyama T, Teramoto S, Hachiga K, Yamashita T, Kwak S. Co-occurrence of TDP-43 mislocalization with reduced activity of an RNA editing enzyme, ADAR2, in aged mouse motor neurons. PLoS One. 2012; 7: E43469
189. Sephton C F, Cenik C, Kucukural A, Dammer E B, Cenik B, Han Y, et al. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. JBiol Chem. 2011; 286: 1204-15
190. Yamashita T, Hideyama T, Teramoto S, Kwak S. The abnormal processing of TDP-43 is not an upstream event of reduced ADAR2 activity in ALS motor neurons. Neurosci Res. 2012; 73: 153-60
191. Kawahara Y, Zinshteyn B, Sethupathy P, Iizasa H, Hatzigeorgiou AG, Nishikura K. Redirection of silencing targets by adenosine-To-inosine editing of miRNAs. Science. 2007; 315: 1137-40
192. Peng Z, Cheng Y, Tan BC, Kang L, Tian Z, Zhu Y, et al. Comprehensive analysis of RNA-Seq data reveals extensive RNA editing in a human transcriptome. Nat Biotechnol. 2012; 30: 253-60
193. Alon S, Mor E, Vigneault F, Church GM, Locatelli F, Galeano F, et al. Systematic identification of edited microRNAs in the human brain. Genome Res. 2012; 22: 1533-40
194. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee J J, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9: 654-9
195. Lotvall J, Valadi H. Cell-To-cell signalling via exosomes through esRNA. Cell Adh Migr. 2007; 1: 156-8
196. Kondo A, Iwaki T, Tateishi J, Kirimoto K, Morimoto T, Oomura I. Accumulation of neurofilaments in a sporadic case of amyotrophic lateral sclerosis. Jpn J Psychiatry Neurol. 1986; 40: 677-84
197. Chow C Y, Landers J E, Bergren S K, Sapp P C, Grant AE, Jones JM, et al. Deleterious variants of FIG4, aphosphoinositide phosphatase, in patients with ALS. Am J Hum Genet. 2009; 84: 85-8
198. Greenway M J, Andersen P M, Russ C, Ennis S, Cashman S, Donaghy C, et al. ANG mutations segregate with familial and ' sporadic' amyotrophic lateral sclerosis. Nat Genet. 2006; 38: 411-3
199. Couthouis J, Hart MP, Erion R, King OD, Diaz Z, Nakaya T, et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet. 2012; 21: 2899-911
200. Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004; 74: 1128-35
201. Rutherford N J, Zhang YJ, Baker M, Gass J M, Finch N A, Xu YF, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008; 4: E1000193
202. Figlewicz D A, Krizus A, Martinoli M G, Meininger V, Dib M, Rouleau GA, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet. 1994; 3: 1757-61
203. Gros-Louis F, Lariviere R, Gowing G, Laurent S, Camu W, Bouchard JP, et al. Aframeshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. JBiol Chem. 2004; 279: 45951-6
204. Parkinson N, Ince PG, Smith MO, Highley R, Skibinski G, Andersen PM, et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology. 2006; 67: 1074-7
205. Munch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology. 2004; 63: 724-6
206. Nishimura AL, Mitne-Neto M, Silva H C, Richieri-Costa A, Middleton S, Cascio D, et al. Amutation in the vesicletrafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2004; 75: 822-31
207. Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2011; 68: 1440-6
208. Yang Y, Hentati A, Deng H X, Dabbagh O, Sasaki T, Hirano M, et al. The gene encoding alsin, aprotein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 2001; 29: 160-5
209. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, et al. Agene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet. 2001; 29: 166-73
210. Mitchell J, Paul P, Chen H J, Morris A, Payling M, Falchi M, et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-Amino acid oxidase. Proc Natl Acad Sci U S A. 2010; 107: 7556-61
211. Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats KA, Laird AS, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med. 2012; 18: 1418-22
212. Orlacchio A, Babalini C, Borreca A, Patrono C, Massa R, Basaran S, et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain. 2010; 133: 591-8
213. Hand CK, Khoris J, Salachas F, Gros-Louis F, Lopes AA, Mayeux-Portas V, et al. Anovel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet. 2002; 70: 251-6
214. Hentati A, Ouahchi K, Pericak-Vance MA, Nijhawan D, Ahmad A, Yang Y, et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics. 1998; 2: 55-60
215. Sapp P C, Hosler B A, McKenna-Yasek D, Chin W, Gann A, Genise H, et al. Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am J Hum Genet. 2003; 73: 397-403